Comparison of long-term outcomes of balloon angioplasty with or without stent placement for hepatic vein type Budd-Chiari syndrome.


Journal

European journal of gastroenterology & hepatology
ISSN: 1473-5687
Titre abrégé: Eur J Gastroenterol Hepatol
Pays: England
ID NLM: 9000874

Informations de publication

Date de publication:
01 12 2021
Historique:
pubmed: 18 8 2021
medline: 12 4 2022
entrez: 17 8 2021
Statut: ppublish

Résumé

To compare percutaneous transluminal balloon angioplasty (PTBA) alone with PTBA plus stent placement for Budd-Chiari syndrome (BCS) patients with short-segmental obstruction of hepatic vein. Between May 2001 and December 2010, 91 hepatic vein type BCS patients (mean age, 32.8 ± 10.8; M:F ratio 50:41) were included and divided into two groups (PTBA alone, as group A, n = 48; PTBA plus stent, as group B, n = 43). The incidence of restenosis, long-term patency, and survival were evaluated. All 91 patients were successfully treated with hepatic vein recanalization. During follow-up period (median 161 months, range: 84-234), group B had a significantly higher proportion of hepatic vein restenosis (56%, 24/43) than group A (33%, 16/48; P < 0.05). Cumulative primary patency rates at 1, 5, 10, 15 years were 96%, 81%, 69%, 65% and 91%, 60%, 47%, 47% in group A and group B, respectively (log-rank P < 0.05). Secondary technical success rates of target hepatic vein were 93% and 57% in group A and group B, respectively (P < 0.05). Clinical complete response rates were 94% and 86% in group A and group B, respectively (P > 0.05). The 15-year cumulative survival rates were 98% and 95% in group A and group B, respectively (P > 0.05). Major procedure-related complications occurred in 3 (3%) patients (1 in group A, 2 in group B). Hepatic vein recanalization is safe and efficient for hepatic vein type BCS patients with hepatic vein short segmental obstruction. Restenosis after hepatic vein stenting is more common and difficult to manage than that after hepatic vein balloon angioplasty alone.

Identifiants

pubmed: 34402468
doi: 10.1097/MEG.0000000000002277
pii: 00042737-202112001-00115
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e843-e850

Informations de copyright

Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Références

European Association for the Study of the Liver. Electronic address eee. EASL Clinical Practice Guidelines: vascular diseases of the liver. J Hepatol 2016; 64:179–202.
Darwish Murad S, Plessier A, Hernandez-Guerra M, Fabris F, Eapen CE, Bahr MJ, et al.; EN-Vie (European Network for Vascular Disorders of the Liver). Etiology, management, and outcome of the Budd-Chiari syndrome. Ann Intern Med 2009; 151:167–175.
Eapen CE, Velissaris D, Heydtmann M, Gunson B, Olliff S, Elias E. Favourable medium term outcome following hepatic vein recanalisation and/or transjugular intrahepatic portosystemic shunt for Budd Chiari syndrome. Gut 2006; 55:878–884.
Ding PX, Zhang SJ, Li Z, Fu MT, Hua ZH, Zhang WG. Long-term safety and outcome of percutaneous transhepatic venous balloon angioplasty for Budd-Chiari syndrome. J Gastroenterol Hepatol 2016; 31:222–228.
Cui YF, Fu YF, Li DC, Xu H. Percutaneous recanalization for hepatic vein-type Budd-Chiari syndrome: long-term patency and survival. Hepatol Int 2016; 10:363–369.
Simonetto DA, Singal AK, Garcia-Tsao G, Caldwell SH, Ahn J, Kamath PS. ACG Clinical Guideline: disorders of the hepatic and mesenteric Circulation. Am J Gastroenterol 2020; 115:18–40.
Hemachandran N, Shalimar, Acharya S, Kedia S, Gunjan D, Saraya A, et al. Long-term outcomes of endovascular interventions in more than 500 patients with Budd-Chiari syndrome. J Vasc Interv Radiol 2021; 32:61–69.e1.
Zanetto A, Pellone M, Senzolo M. Milestones in the discovery of Budd-Chiari syndrome. Liver Int 2019; 39:1180–1185.
Simonetto DA, Singal AK, Garcia-Tsao G, Caldwell SH, Ahn J, Kamath PS. ACG Clinical Guideline: disorders of the hepatic and mesenteric circulation. Am J Gastroenterol 2020; 115:18–40.
Tripathi D, Macnicholas R, Kothari C, Sunderraj L, Al-Hilou H, Rangarajan B, et al. Good clinical outcomes following transjugular intrahepatic portosystemic stent-shunts in Budd-Chiari syndrome. Aliment Pharmacol Ther 2014; 39:864–872.
Wang Q, Li K, He C, Yuan X, Luo B, Qi X, et al. Angioplasty with versus without routine stent placement for Budd-Chiari syndrome: a randomised controlled trial. Lancet Gastroenterol Hepatol 2019; 4:686–697.
Fu YF, Li Y, Cui YF, Wei N, Li DC, Xu H. Percutaneous recanalization for combined-type Budd-Chiari syndrome: strategy and long-term outcome. Abdom Imaging 2015; 40:3240–3247.
Faraoun SA, Boudjella Mel A, Debzi N, Afredj N, Guerrache Y, Benidir N, et al. Budd-Chiari syndrome: a prospective analysis of hepatic vein obstruction on ultrasonography, multidetector-row computed tomography and MR imaging. Abdom Imaging 2015; 40:1500–1509.
Han G, Qi X, Zhang W, He C, Yin Z, Wang J, et al. Percutaneous recanalization for Budd-Chiari syndrome: an 11-year retrospective study on patency and survival in 177 Chinese patients from a single center. Radiology 2013; 266:657–667.
Filippiadis DK, Binkert C, Pellerin O, Hoffmann RT, Krajina A, Pereira PL. Cirse quality assurance document and standards for classification of complications: the cirse classification system. Cardiovasc Intervent Radiol 2017; 40:1141–1146.
Sacks D, McClenny TE, Cardella JF, Lewis CA. Society of Interventional Radiology clinical practice guidelines. J Vasc Interv Radiol 2003; 14:S199–S202.
Tripathi D, Sunderraj L, Vemala V, Mehrzad H, Zia Z, Mangat K, et al. Long-term outcomes following percutaneous hepatic vein recanalization for Budd-Chiari syndrome. Liver Int 2017; 37:111–120.
Zhang CQ, Fu LN, Xu L, Zhang GQ, Jia T, Liu JY, et al. Long-term effect of stent placement in 115 patients with Budd-Chiari syndrome. World J Gastroenterol 2003; 9:2587–2591.
Seijo S, Plessier A, Hoekstra J, Dell’era A, Mandair D, Rifai K, et al.; European Network for Vascular Disorders of the Liver. Good long-term outcome of Budd-Chiari syndrome with a step-wise management. Hepatology 2013; 57:1962–1968.

Auteurs

Xuedong Sun (X)

School of Medicine, Nankai University, Tianjin.

Jinlong Zhang (J)

Department of Interventional Radiology, The First Medical Center, Chinese PLA General Hospital, Beijing, P.R. China.

Feng Duan (F)

Department of Interventional Radiology, The First Medical Center, Chinese PLA General Hospital, Beijing, P.R. China.

Maoqiang Wang (M)

School of Medicine, Nankai University, Tianjin.
Department of Interventional Radiology, The First Medical Center, Chinese PLA General Hospital, Beijing, P.R. China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH